Cochrane Database of Systematic Reviews 2005
DOI: 10.1002/14651858.cd003229.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Phlebotonics for venous insufficiency

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
44
1
4

Year Published

2008
2008
2020
2020

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 57 publications
(49 citation statements)
references
References 51 publications
0
44
1
4
Order By: Relevance
“…So, in Scandinavia drugs are hardly ever prescribed for chronic venous disease [9]. In Spain, for certain phlebotonics the indication for CVI has been withdrawn, and for several other countriessuch as diosmine, hidrosmine, escin, and some rutosides-the use during exacerbations of CVI has been limited to two or three months [10].…”
Section: Sirmentioning
confidence: 99%
See 2 more Smart Citations
“…So, in Scandinavia drugs are hardly ever prescribed for chronic venous disease [9]. In Spain, for certain phlebotonics the indication for CVI has been withdrawn, and for several other countriessuch as diosmine, hidrosmine, escin, and some rutosides-the use during exacerbations of CVI has been limited to two or three months [10].…”
Section: Sirmentioning
confidence: 99%
“…The action mechanisms are not well established [6,10,11] and not clearly understandable theoretically. The smooth muscles (SM) of large and medium-sized veins studied in vitro had no tone and did not relax under the impact of vasodilators [12].…”
Section: Sirmentioning
confidence: 99%
See 1 more Smart Citation
“…Most of these drugs are natural flavonoids extracted from plants. [25] Synthetic products with flavonoid-like properties are also used. There are not enough evidences that they have any role in the prevention of venous ulcers.…”
Section: Phlebotonicsmentioning
confidence: 99%
“…No evidence was obtained to recommend global use of phlebotonic drugs in cases of CVI. They helped in relieving edema in some studies, but this was of uncertain clinical relevance[31] (evidence Level A). Gastrointestinal disorders were the most common adverse event.…”
Section: Phlebotonics/flavonoidsmentioning
confidence: 99%